(Q44381066)

2 December 2017

0 references

1 reference

title

HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy (English)

1 reference

2 December 2017

Claudio Puoti

1

1 reference

PubMed ID

12663249

2 December 2017

language of work or name

1 reference

1 April 2003

1 reference

2 December 2017

Journal of Hepatology

1 reference

2 December 2017

38

1 reference

2 December 2017

529-532

1 reference

2 December 2017

4

1 reference

Therapy of hepatitis C: patients with normal aminotransferase levels

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Treatment of patients with chronic hepatitis C and normal ALT levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

Interferon for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900018-7

7 January 2021

10.1016/S0168-8278(03)00018-7

Identifiers

DOI

1 reference

2 December 2017

1 reference

PubMed ID

12663249